Could home sexually transmitted infection specimen collection with e-prescription be a cost-effective strategy for clinical trials and clinical care?

The results indicate that electronic systems for testing sexually transmitted infections (eSTI) will likely be more cost-effective (a lower cost per STI detected) than clinic-based STI screening, in the context of clinical trials and routine clinical care. The results are promising; a comparative effectiveness trial is needed to determine actual cost and impact of an eSTI on identification, treatment and prevention of infections.